Analysts expect that M.D.C. Holdings, Inc. (NYSE:MDC) will report earnings of $0.60 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for M.D.C.’s earnings. The lowest EPS estimate is $0.48 and the highest is $0.69. M.D.C. posted earnings of $0.63 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 4.8%. The company is expected to issue its next earnings report after the market closes on Tuesday, April 30th.
On average, analysts expect that M.D.C. will report full-year earnings of $3.25 per share for the current year, with EPS estimates ranging from $2.62 to $3.94. For the next fiscal year, analysts anticipate that the business will post earnings of $3.23 per share, with EPS estimates ranging from $2.71 to $3.85. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover M.D.C..
M.D.C. (NYSE:MDC) last released its earnings results on Thursday, January 31st. The construction company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.14 by ($0.19). The business had revenue of $858.49 million for the quarter, compared to the consensus estimate of $839.29 million. M.D.C. had a return on equity of 14.50% and a net margin of 6.93%.
In other M.D.C. news, Director David Siegel sold 2,900 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $28.18, for a total value of $81,722.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO David D. Mandarich sold 55,000 shares of the business’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $29.65, for a total transaction of $1,630,750.00. The disclosure for this sale can be found here. Insiders sold 194,089 shares of company stock valued at $5,611,678 over the last 90 days. 26.30% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in M.D.C. by 26.1% in the third quarter. JPMorgan Chase & Co. now owns 240,131 shares of the construction company’s stock worth $7,103,000 after purchasing an additional 49,732 shares in the last quarter. CVentures Inc. bought a new position in M.D.C. in the fourth quarter worth about $206,427,000. Meeder Asset Management Inc. bought a new position in M.D.C. in the fourth quarter worth about $173,000. Vanguard Group Inc. raised its holdings in M.D.C. by 1.1% in the third quarter. Vanguard Group Inc. now owns 5,408,996 shares of the construction company’s stock worth $159,998,000 after purchasing an additional 57,224 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in M.D.C. by 2.5% in the third quarter. Bank of New York Mellon Corp now owns 1,165,818 shares of the construction company’s stock worth $34,486,000 after purchasing an additional 28,974 shares in the last quarter. Institutional investors and hedge funds own 84.61% of the company’s stock.
Shares of MDC stock traded up $0.13 on Monday, hitting $31.34. The stock had a trading volume of 190,360 shares, compared to its average volume of 412,363. The company has a debt-to-equity ratio of 0.70, a current ratio of 9.15 and a quick ratio of 2.49. The company has a market capitalization of $1.92 billion, a P/E ratio of 8.54, a PEG ratio of 1.16 and a beta of 1.33. M.D.C. has a one year low of $25.14 and a one year high of $33.47.
M.D.C. Company Profile
M.DC Holdings, Inc, through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name.
Featured Story: What is channel trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.